Genmab
GMAB
50.60
-0.75
-1.46%
Genmab
US · GMAB
#860 by market cap
Listed 2019
50.60
-0.75
-1.46%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:56
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q4).
- Total institutional ownership fell 0.3 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 61.61% -0.25pp
- Institutions
- 627 -3
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund42.53%
Hedge Fund12.90%
Government Pension Fund1.95%
VC/PE Fund1.51%
Sovereign Wealth Fund1.25%
Individual/Insider1.10%
Private Company0.66%
Public Company0.53%
Insurance Company0.21%
Other37.35%
Top holders as of 2026-09-30
BlackRock
6.81% · 43.13M sh
Orbis Investment Management Limited
6.67% · 42.23M sh
Darwin Global Management Limited
5.71% · 36.15M sh
Vanguard Capital Management, LLC
3.72% · 23.52M sh
Paradigm Biocapital Advisors LP
2.23% · 14.14M sh
Wellington Management Group
2.08% · 13.17M sh
AllianceBernstein
2.02% · 12.76M sh
Baillie Gifford
1.39% · 8.81M sh
Amundi Asset Management
1.34% · 8.02M sh
Norges Bank Investment Management
1.23% · 7.76M sh
Harding Loevner LP
1.33% · 7.95M sh
Deerfield Management Company, L.P.
1.08% · 6.87M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
3 filings tracked · 0 buys · 3 sells
| Name | Role | Stake |
|---|---|---|
| Judith Klimovsky | Chief Development Officer | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | Judith Klimovsky | Chief Development Officer | Intent to Sell (Form 144) | -1,265 | $556.78 |
| 2025-06-16 | Judith Klimovsky | Chief Development Officer | Intent to Sell (Form 144) | -1,300 | $51.69 |
| 2024-02-29 | Judith Klimovsky | Chief Development Officer | Intent to Sell (Form 144) | -1,200 | $27.77 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:56:12 · For reference only, not investment advice and not tailored to your situation.
Genmab discussion 0 comments